Navigation Links
Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
Date:5/4/2012

sdexamfetamine Dimesylate on Symptoms of Hyperactivity/Impulsivity and Inattention in Children and Adolescents with ADHD
Poster #NR4-16
  • May 6, 2012; 1:00 pm to 3:00 pm EDT
    Lisdexamfetamine Dimesylate Impact on 2 Subjective Quality-of-Life Scales in Adult Attention-Deficit/Hyperactivity Disorder and Executive Dysfunction
    Poster #NR4-17
  • May 6, 2012; 1:00 pm to 3:00 pm EDT
    Efficacy of Lisdexamfetamine Dimesylate on Self- and Informant-Reported Executive Dysfunction in Adults with Attention-Deficit/Hyperactivity Disorder
    Poster #NR4-21

  • Guanfacine Extended Release

    • May 6, 2012; 1:00 pm to 3:00 pm EDT
      Efficacy of Guanfacine Extended Release Administered in the Morning or Evening as Assessed by the Conners' Parent Rating Scale-Revised: Short Form
      Poster Presentation #NR4-15
    • May 6, 2012; 1:00 pm to 3:00 pm EDT
      ADHD Symptoms During Morning, Afternoon, and Evening with Guanfacine Extended Release Treatment Administered in the AM or PM
      Poster Presentation #NR4-20

    Health Economics and Outcomes Research

    • May 6, 2012; 1:00 pm to 3:00 pm EDT
      A Comparison of Rates and Reasons for Urgent Care Utilization Among Children with ADHD Treated with Atypical Antipsychotics vs. Non-Antipsychotics
      Poster Presentation #NR4-12
    • May 6, 2012; 1:00 pm to 3:00 pm EDT
      Urgent Care Utilization for Adolescents Treated with Atypical Antipsychotics vs. Non-Antipsychotics: A Comparison of Rates and Reasons
      Poster Presentation #NR4-18
    • May 6, 2012; 1:00 pm to 3:00 pm EDT
      The Hidden Costs of Attention Deficit/Hyperactivity Disorder (ADHD): A Focus on School and Work in the United States
      Poster Presentation #NR4-19
    • May 8, 2012; 9:00 am to 10:30 am EDT
      Determining an Optimal Cut-Off Score for the WFIRS-P Using ROC Curve Analysis
      Poster Presentation #NR8
      '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
    2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
    3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
    4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
    5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
    6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
    7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
    8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
    9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
    10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
    11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
    (Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
    ... K-V Pharmaceutical Company (NYSE:  KVa/KVb) (the "Company") today announced that ... U.S. Healthcare II, L.L.C. (together the "Lenders") that grant Lenders ... Company,s Class A Common Stock, par value $.01 per share ... second warrant to Lenders that grants Lenders the right to ...
    ... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced its unaudited financial results ... ("2Q FY2010"). 2Q FY20 10 ... increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million). ...
    Cached Medicine Technology:K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 2K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 3K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 4K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 5K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 6K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 7K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 8K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 9K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14
    (Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
    (Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
    (Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
    (Date:4/16/2014)... of the embryo. It begins as a glob of identical ... become the cells of our lungs, muscles, nerves and all ... a feat of reverse tissue engineering, Stanford University researchers have ... cells to proliferate and transform into all of the specialized ...
    (Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
    Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
    ... involved in cancer, aging , , MONDAY, Sept. 1 (HealthDay ... active region of telomerase, an enzyme involved in both ... repeats of a short DNA sequence to the ends ... damage and loss of genetic information during cell division. ...
    ... appear to be at higher risk for psychiatric ... children, according to a report in the September ... one of the JAMA/Archives journals. In addition, low-birth-weight ... to have attention problems than suburban low-birth-weight children. ...
    ... the East coast distribute formula sample packs to new ... concerned about the potential for distributing these packs to ... September issue of Archives of Pediatrics & Adolescent ... practice is changing significantly. , "Packaged as smart diaper ...
    ... found it predicted outcome months after patient went home ... who sleep during the day while in rehabilitation have ... study, which was expected to be published in the ... the sleeping patterns and other predictors of recovery (e.g., ...
    ... drug from a biodegradable polymer , , MONDAY, Sept. 1 ... artery-opening, drug-eluting stents appears equally effective as older models ... study shows. , Stents are tiny mesh tubes inserted ... medicines that help prevent reclosure. The latest form of ...
    ... of a former U.S. soldier whose traumatic brain injuries (TBIs) were ... years after his discharge. The soldier, who suffered several concussions during ... and hearing/visibility issues on a daily basis. , ... ...
    Cached Medicine News:Health News:Secrets of Telomerase Revealed 2Health News:Study examines relationship between low birth weight and psychiatric problems in children 2Health News:Hospitals provide formula sample packs while medical organizations encourage breastfeeding 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2Health News:New Type of Stent Appears Safe, Effective 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 3Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 4
    ...
    ...
    ...
    ... The KyphX Xpander Inflatable Bone Tamp is ... cancellous bone while resisting puncture. Like an ... X-ray image guidance because it is inflated ... contrast medium increases the balloon volume. The ...
    Medicine Products: